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Background: Insulin receptor substrate 1 (IRS-1) is a signaling molecule that exerts a key role in mediating cross talk
between estrogen receptor a (ERa) and insulin-like growth factor 1 (IGF-1) in breast cancer cells. Previously, we
demonstrated that a fraction of IRS-1 binds ERa, translocates to the nucleus, and modulates ERa-dependent
transcription at estrogen response elements (ERE). Here, we studied structure–function relationships of the ERa:IRS-1
complex under IGF-1 and/or estradiol (E2) stimulation.
Materials and methods: ERa and IRS-1 deletion mutants were used to analyze structural and functional ERa/IRS-1
interactions. IRS-1 binding to ERE and IRS-1 role in ERa-dependent ERE transcription was examined by chromatin
immunoprecipitation and gene reporter analysis, respectively. The requirement for IRS-1 in ERa function was tested
with RNAi technology.
Results: Nuclear translocation of IRS-1 was induced by E2, IGF-1, and a combination of both stimuli. ERa/IRS-1
binding was direct and involved the activation function-1 (AF-1)/DNA binding domain (DBD) region of ERa and two
discrete regions of IRS-1 (the N-terminal pleckstrin homology domain and a region within the C-terminus). IRS-1 knock
down abrogated IGF-1-dependent transcriptional activity of unliganded ERa, but induced the activity of liganded ERa.
Conclusions: ERa/IRS-1 interactions are direct and involve the ERa AF-1/DBD domain and IRS-1 domains mapping
within N- and C-terminus. IRS-1 may act as a repressor of liganded ERa and coactivator of unliganded ERa.
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introduction
Insulin-like growth factor-1 (IGF-1) and 17-b-estradiol (E2)
have been shown to act in synergy, stimulating breast cancer
cell growth and survival [1, 2]. The functional interactions
between E2 and IGF-1 signaling systems involve several
transcriptional and posttranscriptional mechanisms. For
example, IGF-1 can affect estrogen receptor a (ERa) action by
enhancing its expression and potentiating its transcriptional
activity in a ligand-independent manner [3–7]. On the other
hand, E2 can enhance IGF-1 signaling by upregulating the
expression of IGF-1 [8], IGF-1 receptor [9], and some IGF-1
binding proteins [10]; ERa also stimulates transcription and
enhances stability of insulin receptor substrate 1 (IRS-1),
a major IGF-1 signaling molecule [11–13].
IRS-1 is a 130–180 kDa docking protein containing two
conserved domains within the N-terminal portion. The PH
(pleckstrin homology) domain mediates interactions with
phospholipids and proteins containing acidic motifs. The
phosphotyrosine-binding (PTB) domain couples IRS-1 with
the phosphorylated IGF-1 receptor. The IRS-1 C-terminus
contains several serine and tyrosine residues that can
modulate its activity. The major intracellular pathways
stemming from IRS-1 are activated upon its tyrosine
phosphorylation and subsequent recruitment of downstream
signaling molecules through Src homology domain-type
interactions [14, 15].
Numerous studies have shown that in breast cancer cells,
IRS-1 signaling regulates cell proliferation, survival, and
drug resistance. IRS-1 is also a key molecule sustaining efficient
E2/IGF-1 cross talk [11, 16]. Recently, we described that in
addition to its function as a signaling molecule, IRS-1 might
affect nuclear processes. Specifically, IRS-1 can be found in
the nucleus in breast cancer cells where it can interact with
ERa. In breast tumors, nuclear colocalization of IRS-1 and
ERa negatively correlated with tumor grade, size, mitotic
index, and lymph node involvement in ductal breast cancer
tissues [17]. The function of nuclear IRS-1 in the regulation
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indicated that nuclear IRS-1 can act as transcriptional
regulator of liganded ERa at estrogen response elements
(ERE) in DNA [18].
In this study, we examined how E2, IGF-1, and the
combination of both factors regulate IRS-1 nuclear
translocation, its binding with ERa, and its effects on ERa-
mediated transcription. Furthermore, using different deletion
mutants of IRS-1 and ERa, we characterized structure–function
relationships in the ERa:IRS-1 complex.
methods and results
E2 and IGF-1 modulate nuclear translocation of
IRS-1 and its recruitment to ERE sites
Previously, we reported that IRS-1 colocalizes and coprecipitates with
ERa in ER-positive MCF-7 cells and that a fraction of IRS-1 can be
translocated to the nucleus together with liganded ERa [18]. Here, we
asked whether IRS-1 could be transported to the nucleus in response to
IGF-1 or IGF-1 plus E2 treatments. Under serum-free medium
conditions, IRS-1 was present mainly in the cytoplasm. The addition of
E2 for 1 or 4 h significantly increased nuclear abundance of IRS-1 and
reduced its cytoplasmic content (Figure 1A). Similar effects were seen
with the combination of E2 and IGF-1. IGF-1 alone minimally increased
IRS-1 nuclear translocation at 4 h (Figure 1A).
Next, we analyzed the association of IRS-1 with ERE sequences within
the pS2 gene promoter (Figure 1B). We found that E2 stimulated IRS-1
loading on pS2 ERE from 1 h to 12 h, reaching the maximum at 4 h,
which was concomitant with the increased nuclear translocation of IRS-1
(Figure 1A and B). On the other hand, IGF-1 stimulation produced two
peaks in the IRS-1 binding on pS2 ERE promoter, at 4 h and 12 h. The
addition of E2 significantly improved IGF-1-induced recruitment of IRS-1
on pS2 ERE at 4 h. Interestingly, at 8 h, IRS-1 was loaded on pS2 in
response to E2 but not under IGF-1 or E2 plus IGF-1, indicating
involvement of IRS-1 in IGF-1 signaling at these time points.
characteristics of the ERa:IRS-1 complex
To characterize the region of IRS-1 responsible for ERa binding under
different stimuli, we employed IRS-1 truncation mutants (depicted in
Figure 2A) [15]. The glutathione S-transferase fusion protein
incorporating IRS-1 (GST-IRS-1) mutants were incubated with 100 lg of
either cytoplasmic or nuclear proteins obtained from MCF-7 cells
stimulated with E2 and/or IGF-1, or left untreated. In unstimulated cells,
the strongest ERa binding mapped within the first 300 amino acids of IRS-1
(M1); a less efficient binding was also detected with the last 500 amino
acids corresponding to the mutants M4 and M5 (Figure 2B). The IRS-1
M1 region contains the PH domain and a portion of the PTB domain
[14, 19]. The absence of binding with the M2 mutant, containing 97
amino acids of the PTB domain, indicates that this domain is not
involved in ERa/IRS-1 interactions (Figure 2B). ERa binding to IRS-1
M1, M4, and M5 domains occurred under all stimulation conditions
(Figure 2C), indicating that these interactions are not affected by
conformational changes and/or phosphorylation induced by stimulation
with IGF-1 and/or E2. The question whether ERa/IRS-1 binding is direct
or requires other proteins was addressed with by incubating GST-IRS-1
mutants with a synthetic ERa protein. The results demonstrated efficient
ERa binding to M1, and to a lesser extent to M4 and M5 in vitro
(Figure 2D), indicating that ERa directly interacts with IRS-1.
To map ERa regions involved in IRS-1 binding, we first used ERa
deletion mutants lacking the activation function-1 (AF-1)/DNA binding
domain (DBD) or activation function-2 (AF-2) domain [20] (Figure 3).
Using GST pull-down assays, we demonstrated that IRS-1 binds to
AF-1/DBD, but not to AF-2 (Figure 3A and B). Interestingly, stimulation
with E2, IGF-1, or both increased AF-1/DBD/IRS-1 binding in the nucleus,
decreasing their cytoplasmic interactions (Figure 3A). A more detailed
mapping of ERa:IRS-1 interfaces was done using additional GST-ERa
truncation mutants (Figure 3C). Specifically, we tested D1 and D2
mutants that include the AF-1 domain, D3 that includes a part of the
AF-1 domain and the entire DBD, D4 that covers the AF-2 domain and
a part of DBD, and D5 that includes a major portion of the AF-2
domain [21] (Figure 3C). The results confirmed that IRS-1 binds to the
AF-1/DBD domain of ERa (Figure 3D).
effects of IRS-1 knock down on ERa-mediated
transcription at pS2 ERE
To investigate functional interactions between IRS-1 and the ERa AF-1
domain, we employed a luciferase transcription reporter assays (Figure 4).
HeLa cells (ERa negative, IRS-1 positive) were transiently cotransfected
with the ERE-responsive luciferase reporter plasmid and a plasmid
encoding ERa (pSG5-HeG0, Figure 4B), ERa with C-terminal truncation
(encoding ERa AF-1/DBD domain pSG5-HE15, Figure 4C), ERa with
N-terminal truncation (encoding ERa AF-2/DBD domain, pSG5-HE19,
Figure 4D), or an empty vector (pSG5, Figure 4A) [22]. To test the role
of IRS-1 in ERa-mediated transcription, IRS-1 levels were downregulated
by 70% using anti-IRS-1 siRNA, as described before [23]. We observed
a significant increase of E2-induced ERE transcription in the absence of
IRS-1 (Figure 4B). In contrast, downregulation of IRS-1 reduced ERE
Figure 1. Insulin receptor substrate 1 (IRS-1) associates with the pS2 ERE
motif in insulin-like growth factor 1 (IGF-1) and estradiol (E2)-treated
MCF-7 cells. (A) MCF-7 cells synchronized in serum-free medium were
left untreated or were treated with 10 nM E2, and/or 20 ng/ml IGF-1 for
24 h. The abundance and localization of IRS-1 was analyzed by western
blotting using 50 lg of cytoplasmic and nuclear proteins. The purity of
subcellular protein fractions was monitored by probing for glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) and nucleolin, serving as
cytoplasmic and nuclear protein markers, respectively. The antibodies
(Abs) used were described previously [18]. (B) Chromatin
immunoprecipitation assays were carried out as described previously [18].
Briefly, MCF-7 cells were treated with 10 nM E2 and/or 20 ng/ml IGF-1,
for 1, 4, 8, 12, and 24 h. Next, the cells were cross-linked with
paraformaldehyde and chromatin–protein complexes were
immunoprecipitated with a specific IRS-1 Ab. The presence of pS2 ERE in
the resulting immunoprecipitates was analyzed by PCR [18].
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transcription in IGF-1 and IGF-1 plus E2-treated cells (Figure 4B). IRS-I
knock down did not significantly influence ERE-mediated transcription
in HeLa cells expressing the AF-2/DBD region of ERa (Figure 4D), while
a significant decrease of ERa transactivation was observed in cells
expressing the AF-1/DBD region in response to IGF-1 stimulation.
discussion
ERa/IGF-1 cross talk is known to influence breast cancer cell
proliferation, survival, transformation, migration, and
invasion [2, 24, 25]. IRS-1 is a major substrate of the IGF-1
receptor and a crucial molecule mediating ERa/IGF-1
interactions [1, 2, 14]. In breast cancer, IRS-1 overexpression
has been associated with the development of the transformed
phenotype, hormone independence, and drug resistance [2].
These effects have been attributed to increased IRS-1 tyrosine
phosphorylation and potentiation of its signaling through
the antiapoptotic Akt pathway [2, 25]. In addition to its
conventional role as signal transducing molecule, IRS-1 has
been found in the nuclear compartment in several cell types
[15, 17, 18, 26, 27]. Recently, we demonstrated that nuclear
IRS-1 is present in ERa-positive breast tumors and cell lines.
In cellular systems, we found that IRS-1 can interact with
ERa and influence the activity of liganded ERa [18]. Here,
we characterized IRS-1 and ERa domains that are involved
in functional interactions between these molecules and we
studied how IGF-1 can influence nuclear localization of
IRS-1 and its recruitment on ERE-containing promoters
in the presence of liganded or unliganded ERa.
Figure 3. Estrogen receptor a (ERa) domains involved in insulin receptor
substrate 1 (IRS-1) binding. (A) We expressed and purified the GST-ERa
fusion proteins with activation function-1/DNA binding domain or
activation function-2 deletions, as described previously [15]. (B) MCF-7
were left untreated or treated with 10 nM estradiol, and/or 20 ng/ml of
insulin-like growth factor 1 for 24 h. Hundred microgram of cytoplasmic
or nuclear proteins were precipitated with 10 lg of GST (V) or different
GST-ERa truncation mutants coupled to glutathione-Sepharose. IRS-1
and GST content in precipitates were determined by western blotting
(WB). Twenty microgram of total lysates were loaded as control [Lys]).
(C) A more detailed mapping was carried out with shorter GST-ERa
fragments. (D) Cell lysates were precipitated with 10 lg of GST (V) or
different GST-ERa truncation mutants coupled to glutathione-Sepharose.
IRS-1 and GST content in precipitates were determined by WB.
Figure 2. Insulin receptor substrate 1 (IRS-1) domains involved in
estrogen receptor a (ERa) binding; influence of estradiol (E2) and insulin-
like growth factor 1 (IGF-I) treatment. (A) We expressed and purified
GST-IRS-1 fusion proteins according to previously described protocol
[15]. MCF-7 cells synchronized in serum-free medium were left untreated
(B) or treated with 10 nM E2, or 20 ng/ml of IGF-1 or both (C) for 24 h
and then lysed. Hundred microgram of cytoplasmic or nuclear proteins
were precipitated with 10 lg of GST (V) or appropriate GST-IRS-1
truncation mutants coupled to glutathione-Sepharose. The bound proteins
were eluted and analyzed by western blotting (WB) with anti-ERa
monoclonal antibody (mAb) (Santa Cruz Biotechnology Santa Cruz, CA).
Twenty microgram of total lysates were loaded as control (Lysate [Lys]).
Three mutants, amino acids 1–300 (pleckstrin homology/
phosphotyrosine-binding domain), amino acids 701–1000, and amino
acids 931–1233, are positive for the interaction with ERa. All other
mutants and GST alone are negative. (D) Ten nanogram of ERa pure
protein (Promega Madison, WI) was precipitated with 10 lg of GST or
GST-IRS-1 truncation mutants coupled to glutathione-Sepharose.
Precipitates were analyzed by WB with anti-ERa mAb and anti-GST
antibody (Santa Cruz Biotechnology).
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Our results indicated that the interaction between IRS-1
and ERa does not require intermediating proteins as it can occur
in vitro between GST-IRS-1 mutants and synthetic ERa. Two
binding sites for ERa were mapped on IRS-1. One site mapped
within the N-terminal portion of IRS-1 containing the PH
domain, while the second localized within the C-terminus of
IRS-1 [14]. These results are consistent with previously published
observations that nuclear IRS-1 can interact with other proteins
(e.g. the T antigen of JCV virus) via the PH domain [15]. The
binding site for IRS-1 on ERa was mapped in the AF-1/DBD
domain that contains several serine residues responsible of
ligand-independent transactivation of ERa [2, 5, 28]. However,
because the ERa/IRS-1 complex can bind to ERE under E2,
which must engage an unoccupied DBD domain, we speculate
that ERa binding to IRS-1 is mediated mostly by AF-1.
Nuclear translocation of IRS-1 and its interaction with ERE
could be induced by both E2 and IGF-1, but with different
dynamics and efficiency. E2 activates continuous presence of
IRS-1 on ERE, while IGF-1 stimulates intermittent IRS-1
interaction with these sites. Notably, IRS-1 recruitment to ERE
in response to E2 and IGF-1 resembles that of liganded or
unliganded ERa, respectively [29], indicating that IRS-1 and
ERa bind ERE motifs as one complex. The differential
recruitment of the ERa:IRS-1 complex could be explained by
the nature of ERa activation in response to E2 or IGF-1. In
particular, E2 directly activates ERa by binding to the AF-2
domain [30]. Instead, activation of ERa by IGF-1 is indirect
and mediated by Erk1/2 and Akt kinases that phosphorylate
ERa AF-1 domain on serine residues 118 and 167,
respectively [1, 5, 28, 31, 32]. Notably, the recruitment of
Figure 4. Insulin receptor substrate 1 is a transcriptional coregulator of estrogen receptor a. The experiments were carried out using HeLa cells that are ERa
negative and IRS-1 positive. All transfection mixtures contained the reporter plasmid, ERE-Luc, encoding the firefly luciferase complementary DNA under
the control of the TK promoter and three estrogen response element sequences and, as internal control, the plasmid pRL-Tk (Promega) encoding Renilla
reniformis luciferase. The cocktail was cotransfected with either the empty vector pSG5 (A), pSG5-HeG0 encoding ERa (B), pSG5-HE15, and pSG5-HE19,
code for a C-terminal truncated receptor (activation function-1/DNA binding domain (DBD), amino acids 1–281) (C) and for the N-terminal truncated
receptor (activation function-2/DBD, amino acids 179–575) (D), respectively. The luciferase activity was measured using Dual luciferase assay System
(Promega Madison, WI). IRS-1 knock down was obtained by transfecting cells with pSilencer-IRS-1 plasmid (shIRS1) [23] or with a control scrambled
shRNA (Scrambled). Transfections and luciferase assays were carried out as described previously [18]. The results represent mean 6 standard deviation of
five independent experiments.
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IRS-1 on ERE site in response to a combination of IGF-1 and
E2 was greater than that seen with either IGF-1 or E2 alone,
confirming synergistic effects of both mitogens on ERa.
Finally, we investigated the relevance of IRS-1/ERa
interaction in ERa-dependent transcription in response to E2
and/or IGF-1 stimulation. Using IRS-1 RNAi technology, we
confirmed that IRS-1 might act as a repressor of liganded ERa
on ERE [18]. It is worth noting that the effects of IRS-1 knock
down were not noticeable in cells expressing the AF-1 or the
AF-2 truncated mutants of ERa. This is in agreement with IRS-1
function since the absence of IRS-1 reduces the recruitment of
protein kinases that phosphorylate serine residues within the AF-
1 domain inducing ligand-independent activation of ERa [16,
33]. On the other hand, our results indicated that IRS-1 might be
a coactivator of unliganded (IGF-1 transactivated) ERa. The
negative effects of IRS-1 towards liganded ERa were abrogated
under combined E2 plus IGF-1 treatment, indicating that
cooperation of both stimuli might be optimal for ERa
transcriptional response. In conclusion, our data indicate that
IRS-1 interacts directly with ERa in the nucleus of breast cancer
cells and plays a key role in the regulation of balanced
transcription of liganded and unliganded ERa.
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